Azelaic Acid
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Azelaic Acid: Dermatological Agent — No New Indication Predicted
One-Sentence Summary
Azelaic Acid is a naturally occurring dicarboxylic acid commonly used in dermatology for the treatment of acne vulgaris and rosacea. The TxGNN model did not generate any repurposing predictions for this drug, meaning there are currently no computationally suggested new indications. Further data enrichment (mechanism of action, regulatory details) is needed before re-evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Dermatological use (acne, rosacea — based on known pharmacology; specific approved indication text not available in dataset) |
| Predicted New Indication | None — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — no prediction to evaluate |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why Was No Prediction Generated?
Azelaic Acid (DrugBank ID: DB00548) is a dicarboxylic acid with known antibacterial, keratolytic, anti-inflammatory, and tyrosinase-inhibiting properties. It is primarily used as a topical agent for acne vulgaris, rosacea, and hyperpigmentation disorders.
The TxGNN model did not produce any repurposing candidates for this drug. Several factors may explain this:
-
Topical-only use profile: Azelaic Acid is predominantly used topically, which limits its systemic pharmacological interactions captured by the knowledge graph. TxGNN’s drug–disease relationship network may not adequately represent topical-route-specific therapeutic effects.
-
Missing mechanism of action data: The MOA field is absent from the current dataset. Without explicit target–pathway annotations in the knowledge graph, the model’s ability to infer novel disease associations is reduced.
-
Limited knowledge graph connectivity: If Azelaic Acid has few edges (drug–target, drug–disease, drug–drug) in the underlying knowledge graph, the graph neural network has insufficient signal to generate high-confidence predictions.
Clinical Trial Evidence
No predicted indication exists; therefore, no targeted clinical trial search was performed.
Literature Evidence
No predicted indication exists; therefore, no targeted literature search was performed.
Malaysia Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| (Not available in dataset) | (Not available) | (Not available) | (Not available) |
Note: The NPRA query confirmed 2 registrations for Azelaic Acid in Malaysia, but detailed license information (authorization numbers, product names, dosage forms, approved indications) was not captured in the current dataset. Please consult the NPRA Product Search for complete registration details.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current dataset.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model did not generate any repurposing predictions for Azelaic Acid. Without a candidate indication, there is no actionable repurposing hypothesis to evaluate at this time.
To proceed, the following is needed:
- Mechanism of action (MOA) data — Query DrugBank API to obtain target and pathway annotations, which will enrich Azelaic Acid’s representation in the knowledge graph
- Complete Malaysia regulatory details — Retrieve full NPRA license information including product names, dosage forms, and approved indication text
- Package insert safety data — Obtain key warnings, contraindications, and precautions from the approved product labelling
- Knowledge graph connectivity check — Verify that Azelaic Acid (DB00548) exists as a node in the TxGNN knowledge graph (
data/kg.csv) and assess its edge count; if absent or poorly connected, the drug cannot be effectively evaluated by the model - Re-run TxGNN prediction after data enrichment to determine if new indications emerge
This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.